The NINLARO® (ixazomib) Regimen* Provides Durable Strength for Your Patients With Relapsed Multiple Myeloma Who May Benefit From Long-term† Proteasome Inhibition1-3
The first and only FDA-approved oral proteasome inhibitor-based regimen for patients with multiple myeloma at first relapse.1 The NINLARO regimen was studied in a broad range of patients and demonstrated a median PFS of 20.6 months vs 14.7 months with the Rd regimen*.
*The NINLARO regimen included NINLARO + lenalidomide + dexamethasone. The Rd regimen included placebo + lenalidomide + dexamethasone.1
†Used herein to refer to treatment to disease progression or unacceptable toxicity.1
PFS=progression-free survival; PI=proteasome inhibitor.